HOUSTON, May 16, 2019 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today discussed
the use of its Rapid Acoustic Pulse Technology for the removal of
tattoos using the capability of the device to clear the vacuoles
that result from the use of a laser to ablate tattoo ink.
------------------------
Join our more than 200K fans here to
follow the Company: https://soly-investors.com
------------------------
A problem arises the moment that laser light contacts ink
particles within its path. Almost instantly, a plasma event occurs
that quickly results in the formation of steam vacuoles in the
skin. These vacuoles appear white in color and result in "optical
scattering" that immediately blocks any additional laser energy
from reaching ink particles below the vacuoles. Biopsies taken
shortly after laser treatment reveal that, in addition to surface
vacuoles that clear within an hour or less, deeper "dermal
vacuoles" have also formed and shield the remaining particles from
subsequent laser passes. Our studies have shown that these
deep dermal vacuoles persist for up to 48 hours. Until those
vacuoles are gone, we believe subsequent laser passes will have
very little effect.
"When you apply the RAP device immediately following a laser
treatment, histology reveals that both surface vacuoles and the
deep dermal vacuoles are dispersed, allowing lasers to again have
line of sight access to pigment particles," said Dr. Christopher Capelli, President, CEO and
Co-Founder of Soliton, Inc. "Thus, using the Soliton RAP
device immediately after a laser treatment allows for a subsequent
laser treatment in the same office visit, and this cycle may be
repeated multiple times." The RAP device has not been cleared
by the FDA.
"On average, a typical black tattoo can require 10 office visits
to achieve acceptable removal. Our studies have shown this can now
be reduced to just 2-3 visits, and we believe this will have a
significant impact on the tattoo removal market, which is predicted
to reach $4.3 billion by 2023," said
Walter Klemp, Executive Chairman of
Soliton, Inc.
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first planned commercial product is designed to use rapid
pulses of designed acoustic shockwaves in conjunction with existing
lasers to reduce the number of treatment visits to remove unwanted
tattoos (RAP device). In addition, higher energy versions of
acoustic pulse devices are in early stages of development for
potential stand-alone treatment of cellulite and other indications.
Both products are investigational and are not available for sale in
the United States.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of the Soliton RAP
technology, to prove safe and effective at reducing office visits
required to remove a tattoo, for the Company's devices to achieve
FDA clearance for the tattoo indications and the projected size of
the tattoo removal market. These statements relate to future
events, future expectations, plans and prospects. Although Soliton
believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may
prove to have been materially different from the results expressed
or implied by such forward-looking statements. Soliton has
attempted to identify forward-looking statements by terminology
including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under in our SEC filings, including under the heading "Item 1A.
Risk Factors" in the Form 10-K for year ended December 31, 2018 we filed with the SEC and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original
content:http://www.prnewswire.com/news-releases/solitons-rap-device-able-to-penetrate-vacuole-shielding--targets-4-billion-potential-tattoo-removal-market-300851428.html
SOURCE Soliton, Inc.